| 摘要 |
The present invention relates to a new method for predicting cancer response to mTOR related cancer drugs and prognosis of cancer. To this end, the present invention relates to a new method for predicting cancer response to an inhibitor of mTOR, PI3K, PDK1, FKBP12 or Akt, and prognosis of cancer by measuring mutations in NRF2 protein/gene. Namely, the present invention relates to a method for predicting prognosis/response of a cancer patient to an inhibitor of mTOR, PI3K, PDK1, FKBP12 or Akt, comprising: (a) measuring DNA or RNA expression level coding for mutated NRF2 protein or expression level of mutated NRF2 protein in a sample originated from the patient; and (b) predicting the response/prognosis of the cancer patient based on the measured expression level. Also, the present invention includes kits for the above method. |
